Four years after the coronavirus pandemic first began, though numbers of new COVID-19 cases have dramatically dropped off, doctors are now grappling with the virus in two forms: acute COVID infections ...
Moderna’s next-gen COVID vaccine notched a higher immune response than its licensed counterpart, passing a phase 3 test. No data accompanied the company’s announcement Tuesday, with Moderna saying ...
Spikevax is now approved for all adults aged 65 years and older, and individuals aged 6 months through 64 years at increased risk for COVID-19 disease CAMBRIDGE, MA / ACCESS Newswire / July 10, 2025 / ...
July 11, 2025 — The FDA has given full approval to Moderna's COVID-19 shot, Spikevax, allowing it to be used in children 6 months to 11 years old, with some limits on who can get it. First approved in ...
Helen Branswell covers issues broadly related to infectious diseases, including outbreaks, preparedness, research, and vaccine development. Follow her on Mastodon and Bluesky. You can reach Helen on ...
Moderna announced on Friday that its updated COVID-19 mRNA vaccine, Spikevax, has received authorization in Canada for those aged six months and older. The company said that it is on track to deliver ...
Moderna (MRNA) announced “positive” preliminary immunogenicity data for the 2025-2026 formula of Spikevax, which targets the LP.8.1 variant of SARS-CoV-2 to help prevent COVID-19. “The data from an ...
Moderna is deprioritizing its flu/COVID combination vaccine in younger adults amid a push to cut around $1.5 billion from its operating expenses. The biotech disclosed the changes alongside news of a ...
The updated 2024-2025 mRNA COVID vaccine from Moderna does not appear to carry the same risk for myocarditis in young adults that the first mRNA COVID vaccines did, suggested research presented at the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback